Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2021(H SHARES)

10/07/2021 | 04:57am EST

FF301

Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

For the month ended:

30

September 2021

Status: New Submission

To : Hong Kong Exchanges and Clearing Limited

Name of Issuer:

上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (a joint stock limited company incorporated in the PRC with limited liability)

Date Submitted:

07

October 2021

I. Movements in Authorised / Registered Share Capital

1. Type of shares

Ordinary shares

Class of shares

Class H

Listed on SEHK (Note 1)

Yes

Stock code

02196

Description

Number of authorised/registered shares

Par value

Authorised/registered share capital

Balance at close of preceding month

551,940,500

RMB

1

RMB

551,940,500

Increase / decrease (-)

0

RMB

0

Balance at close of the month

551,940,500

RMB

1

RMB

551,940,500

2. Type of shares

Ordinary shares

Class of shares

Class A

Listed on SEHK (Note 1)

No

Stock code

600196

Description

Number of authorised/registered shares

Par value

Authorised/registered share capital

Balance at close of preceding month

2,010,958,045

RMB

1

RMB

2,010,958,045

Increase / decrease (-)

0

RMB

0

Balance at close of the month

2,010,958,045

RMB

1

RMB

2,010,958,045

Total authorised/registered share capital at the end of the month:

RMB

2,562,898,545

Page 1 of 6

v 1.0.0

FF301

II. Movements in Issued Shares

1. Type of shares

Ordinary shares

Class of shares

Class H

Listed on SEHK (Note 1)

Yes

Stock code

02196

Description

Balance at close of preceding month

551,940,500

Increase / decrease (-)

0

Balance at close of the month

551,940,500

2. Type of shares

Ordinary shares

Class of shares

Class A

Listed on SEHK (Note 1)

No

Stock code

600196

Description

Balance at close of preceding month

2,010,958,045

Increase / decrease (-)

0

Balance at close of the month

2,010,958,045

Page 2 of 6

v 1.0.0

FF301

III. Details of Movements in Issued Shares

(A). Share Options (under Share Option Schemes of the Issuer) Not applicable

(B). Warrants to Issue Shares of the Issuer which are to be Listed Not applicable

(C). Convertibles (i.e. Convertible into Issue Shares of the Issuer which are to be Listed) Not applicable

(D). Any other Agreements or Arrangements to Issue Shares of the Issuer which are to be listed, including Options (other than Share Options Schemes) Not applicable

(E). Other Movements in Issued Share Not applicable

Page 3 of 6

v 1.0.0

FF301

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

Page 4 of 6

v 1.0.0

FF301

V. Confirmations

We hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued by the issuer during the month as set out in Part III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and, insofar as applicable:

(Note 2)

  1. all money due to the listed issuer in respect of the issue of securities has been received by it;
  2. all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled;
  3. all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
  4. all the securities of each class are in all respects identical (Note 2);
  5. all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;
  6. all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
  7. completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
  8. the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Submitted by:

Tricor Investor Services Limited

Title:

H Share Registrar

(Director, Secretary or other Duly Authorised Officer)

Notes

  1. SEHK refers to Stock Exchange of Hong Kong.
  2. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, no further confirmation is required to be made in this return.

Page 5 of 6

v 1.0.0

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 07 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 October 2021 08:56:09 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
12/01SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
12/01SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - lapse of implementation period of..
PU
11/26SoftBank in investment talks with Chinese mRNA vaccine firm Abogen - sources
RE
11/26SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
11/25Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
MT
11/24SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement regarding the establishment of inve..
PU
11/24SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction formation of partnership
PU
11/24SHANGHAI FOSUN PHARMACEUTICAL : Revision of annual caps of continuing connected transactio..
PU
11/19China's BioKangtai begins first shipment of AstraZeneca's COVID-19 shot
RE
11/16SHANGHAI FOSUN PHARMACEUTICAL : (1) extension of authorisation period and change of author..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 36 399 M 5 714 M 5 714 M
Net income 2021 4 498 M 706 M 706 M
Net Debt 2021 14 452 M 2 269 M 2 269 M
P/E ratio 2021 31,4x
Yield 2021 0,84%
Capitalization 126 B 19 866 M 19 859 M
EV / Sales 2021 3,87x
EV / Sales 2022 3,20x
Nbr of Employees 32 258
Free-Float 58,1%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 54,37 CNY
Average target price 67,38 CNY
Spread / Average Target 23,9%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman